Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT)

This Phase II study (n=98) found the addition of capecitabine to irinotecan in the treatment of advanced gallbladder cancer did not improve overall survival (median 5.16 months versus 6.28 months with irinotecan monotherapy; p=0.93).

JAMA Oncology